enable monitoring of mutations while informing clinical researchers and regulators. In addition, this may assist with collecting pharmacokinetic and dose finding data 10 . Others suggest that genetically modified phages (GM-phages) may control for random genetic transfers and mutations, thus improving the chances of regulatory success.
Genetically modified phage
Over the past 30 years, phages have proven to be geneticallymalleable tools [11] [12] [13] [14] [15] . New developments using genetic engineering (a.k.a. synthetic biology) to create phages 12 may be relevant to the future of phage CTs. Some researchers compare GM-phages to genetically-programmable machines 16 and, if gene switches are inserted, they may also reduce risks associated with uncontrolled gene transfer 15 . In 2018, the Nobel Prize in Chemistry for was awarded to three scientists for their work in 'phage display of peptides and antibodies' 17, 18 and 'directed evolution' 19 . Some researchers argue that genetic engineering of phages may secure intellectual property and in doing so increase the potential for funding CTs. Moreover, since the discovery of CRISPR/Cas9 there has been a rapid increase in the number of technologies using GM-phages 20 . Functions including conditional expression, conditional replication, and non-integration can be included. Although
it is yet to be demonstrated, such innovation may improve the chances of regulatory approval while also providing an opportunity to create new industry for Australia.
Phage clinical trials
In the recent past, many phage therapy CTs have used traditional 
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Regulatory process in Australia
In Australia, the Therapeutic Goods Administration (TGA) has adopted many of the European Medicines Agency policies. Both natural phage and GM-phage are considered 'gene transfer In Focus biological medicines'. The Australian regulatory process for both natural and GM-phage is shown in Figure 2 However, one benefit of the CTX pathway is that once a CTX application is approved, the sponsor may conduct any number of CTs under that application without further assessment by the TGA.
For any CT, a HREC evaluates whether the risk-benefit ratio is favourable for the participant. To improve the potential benefits to the participant, the product should target a disease of unmet need and have demonstrated safety and efficacy in preclinical studies. In order to make a reasonable assessment, the HREC evaluates at least three essential documents: investigator brochure, trial protocol, and patient informed consent form. The investigator brochure should include both phage-relevant data 8 and published studies that support validity (e.g. randomisation, sample size calculation, and blinded outcome assessments 31, 32 ).
Should the product be a genetically modified organism (GMO), then an alternative pathway will be required. A GMO must first be 
Why Australia?
Australia is considered attractive to international sponsors wishing to conduct CTs because of key financial and logistical frameworks.
The research and development tax incentive scheme provides up to 43.5% reduction in a company's income tax liability and given that the average phase I CT costs greater than $2m, the potential savings are significant. In 2013, Australia setup The National Mutual Acceptance Scheme, which is a Memorandum of Understanding between most states and territories to allow for 'once only' scientific and ethical review for multi-centre CTs conducted at public health organisations. This improves efficiency by reducing duplication. Readers can review the numerous clinical trial documents that the Australian government has provided online [35] [36] [37] .
The translation of phage therapy requires an adaptive approach.
Out of the three components, CT design is easier to adjust than the 
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